> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Continues to Meet Product Review Goals: Hahn
- URL: https://www.fdaweb.com/fda-continues-to-meet-product-review-goals-hahn/
- Published: 2020-06-23T12:00:00.000Z
- Updated: 2026-09-14T16:19:15.000Z
- Author: David McFarland
- Tags: FDA Policy/General, Drugs, Devices, #legacy-id-D5147073

FDA commissioner **Stephen Hahn** says the agency “has maintained the same pace of meeting its goals on review of applications for medical products during the pandemic that it has maintained in recent years.” Writing in an online [post](https://www.fda.gov/news-events/fda-voices/fda-maintains-pace-meeting-its-goals-applications-medical-products-during-pandemic?utm%5Fcampaign=FDA%20Maintains%20the%20Pace%20of%20Meeting%20Its%20Goals%20on%20Applications%20for%20Medical%20Products%20During%20the%20Pandemic&utm%5Fmedium=email&utm%5Fsource=Eloqua) to praise agency staff for their efforts, Hahn says FDA is on target to meet user fee goals for drugs by reviewing and taking timely action on at least 90% of the brand, generic, and biosimilar drug applications, even during the pandemic.

“For many of the medical products we regulate, including medical devices, biologics, and animal drugs, the impact of the pandemic on user fee review timelines has not been significant and, at this time, we anticipate meeting medical device, biologics, and animal drug timeline goals for our decisions on marketing applications, although it is possible we will not be able to sustain our current level of performance indefinitely,” Hahn writes.

Hahn says the staff needs to be sure it is prepared to continue reviewing future applications for all medical products that require premarket review. He says FDA recognizes that potential therapies to treat patients with Covid-19 are a top priority. “Our process for setting priorities will be based on the data supporting a new product, patient safety, and other factors,” he concludes. “We also want to be sure that the manufacturing capacity for therapies to treat patients with Covid-19 receives attention. We also are paying special attention to the review of generic applications for products used to treat Covid-19 patients.”